Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026051 · ClinicalTrials.gov registry record · Phase 2
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
A Phase 2 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01026051 is a Phase 2 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 5 participants.
The verdict
NCT01026051, a Phase 2 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
Interventions
- BIOLOGICAL MKC1106-MT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026051
The ClinicalTrials.gov registry entry for NCT01026051 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MKC1106-MT is the first listed.
NCT01026051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026051 about?
NCT01026051 is a clinical study titled "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma". The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
What is the current status of trial NCT01026051?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01026051?
The interventions under investigation include: MKC1106-MT (BIOLOGICAL).
Who is sponsoring clinical trial NCT01026051?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.